Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards cancer drug development. BioNTech is targeting 2024 revenues in a range of 2.5 billion to 3.1 billion euros, depending among other things on regulatory developments and COVID-19 vaccine uptake, it said in a statement.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles